1-4 of 4
Alice C. Fan
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial

Chung-Han Lee, Robert Motzer, Hamid Emamekhoo, Marc Matrana, Ivor Percent, James J. Hsieh, Arif Hussain, Ulka Vaishampayan, Sandy Liu, Steven McCune, Vijay Patel, Montaser Shaheen, Johanna Bendell, Alice C. Fan, Benjamin A. Gartrell, Oscar B. Goodman, Jr, Petros G. Nikolinakos, Arash Rezazadeh Kalebasty, Yousef Zakharia, Zhentao Zhang, Hema Parmar, Lalith Akella, Keith Orford, Nizar M. Tannir
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (15): 3248–3255.
https://doi.org/10.1158/1078-0432.CCR-22-0061
Published: 02 August 2022
View article titled, Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial
Open the PDF for Telaglenastat plus Everolimus in Advanced Renal Cell Carcinoma: A Randomized, Double-Blinded, Placebo-Controlled, Phase II ENTRATA Trial in another window
Includes: Supplementary data
Journal Articles

Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial

Funda Meric-Bernstam, Nizar M. Tannir, Othon Iliopoulos, Richard J. Lee, Melinda L. Telli, Alice C. Fan, Angela DeMichele, Naomi B. Haas, Manish R. Patel, James J. Harding, Martin H. Voss, Taofeek K. Owonikoko, Bradley Carthon, Ramaprasad Srinivasan, Johanna C. Bendell, Yonchu Jenkins, Sam H. Whiting, Keith Orford, Mark K. Bennett, Todd M. Bauer
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (8): 1540–1548.
https://doi.org/10.1158/1078-0432.CCR-21-2972
Published: 14 April 2022
View article titled, Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial
Open the PDF for Telaglenastat Plus Cabozantinib or Everolimus for Advanced or Metastatic Renal Cell Carcinoma: An Open-Label Phase I Trial in another window
Includes: Supplementary data
Journal Articles

Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion BRCA Mutations among Patients with Advanced Solid Tumors

Neelima Vidula, Thereasa A. Rich, Oliver Sartor, Jennifer Yen, Aaron Hardin, Tracy Nance, Michael B. Lilly, Mohammad Amin Nezami, Sandip P. Patel, Benedito A. Carneiro, Alice C. Fan, Adam M. Brufsky, Barbara A. Parker, Benjamin B. Bridges, Neeraj Agarwal, Benjamin L. Maughan, Victoria M. Raymond, Stephen R. Fairclough, Richard B. Lanman, Aditya Bardia, Massimo Cristofanilli
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (11): 2546–2555.
https://doi.org/10.1158/1078-0432.CCR-19-2933
Published: 01 June 2020
View article titled, Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <em>BRCA</em> Mutations among Patients with Advanced Solid Tumors
Open the PDF for Routine Plasma-Based Genotyping to Comprehensively Detect Germline, Somatic, and Reversion <em>BRCA</em> Mutations among Patients with Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

Nanoscale approaches to define biologic signatures and measure proteomic response to targeted therapies in hematologic and solid tumors

Alice C. Fan, Jessica L. Dermody, Christina Kong, Nancy Zhang, Liwen Xu, John P. Renschler, Mathias W. Orban, Ben Varasteh, Kunju Sridhar, Yasodha Natkunam, Stephen E. Coutre, Peter Greenberg, Dean W. Felsher
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (19_Supplement): PR6.
https://doi.org/10.1158/DIAG-10-PR6
Published: 15 August 2014
View article titled, Nanoscale approaches to define biologic signatures and measure proteomic response to targeted therapies in hematologic and solid tumors